Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

AMS vs IART vs NVCR vs ATRC vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AMS
American Shared Hospital Services

Medical - Care Facilities

HealthcareAMEX • US
Market Cap$13M
5Y Perf.+10.3%
IART
Integra LifeSciences Holdings Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.08B
5Y Perf.-73.3%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-73.5%
ATRC
AtriCure, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$1.33B
5Y Perf.-45.0%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%

AMS vs IART vs NVCR vs ATRC vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AMS logoAMS
IART logoIART
NVCR logoNVCR
ATRC logoATRC
HOLX logoHOLX
IndustryMedical - Care FacilitiesMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$13M$1.08B$2.04B$1.33B$16.97B
Revenue (TTM)$29M$1.64B$674M$552M$4.13B
Net Income (TTM)$-2M$-496M$-173M$-5M$544M
Gross Margin25.0%39.6%75.2%75.5%52.8%
Operating Margin-12.3%5.8%-27.2%-0.4%17.5%
Forward P/E6.2x5.7x428.7x17.2x
Total Debt$23M$2.03B$290M$88M$2.63B
Cash & Equiv.$11M$235M$103M$167M$1.96B

AMS vs IART vs NVCR vs ATRC vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AMS
IART
NVCR
ATRC
HOLX
StockMay 20May 26Return
American Shared Hos… (AMS)100110.3+10.3%
Integra LifeScience… (IART)10026.7-73.3%
NovoCure Limited (NVCR)10026.5-73.5%
AtriCure, Inc. (ATRC)10055.0-45.0%
Hologic, Inc. (HOLX)100142.6+42.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: AMS vs IART vs NVCR vs ATRC vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 4 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. American Shared Hospital Services is the stronger pick specifically for growth and revenue expansion. IART also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
AMS
American Shared Hospital Services
The Income Pick

AMS is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 0 yrs, beta -0.07
  • Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
  • 32.9% revenue growth vs IART's 1.5%
Best for: income & stability and growth exposure
IART
Integra LifeSciences Holdings Corporation
The Value Play

IART ranks third and is worth considering specifically for value.

  • Lower P/E (5.7x vs 428.7x)
Best for: value
NVCR
NovoCure Limited
The Healthcare Pick

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ATRC
AtriCure, Inc.
The Healthcare Pick

Among these 5 stocks, ATRC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
HOLX
Hologic, Inc.
The Long-Run Compounder

HOLX carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 124.3% 10Y total return vs ATRC's 84.4%
  • Lower volatility, beta 0.45, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.45, current ratio 3.75x
  • 13.2% margin vs IART's -30.1%
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthAMS logoAMS32.9% revenue growth vs IART's 1.5%
ValueIART logoIARTLower P/E (5.7x vs 428.7x)
Quality / MarginsHOLX logoHOLX13.2% margin vs IART's -30.1%
Stability / SafetyHOLX logoHOLXBeta 0.45 vs IART's 2.39, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)HOLX logoHOLX+35.3% vs AMS's -28.5%
Efficiency (ROA)HOLX logoHOLX6.1% ROA vs NVCR's -16.5%, ROIC 9.4% vs -16.4%

AMS vs IART vs NVCR vs ATRC vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AMSAmerican Shared Hospital Services
FY 2024
Rental Income from Medical Services
55.1%$16M
Patient Income
44.3%$13M
Equipment Sales
0.5%$155,000
IARTIntegra LifeSciences Holdings Corporation
FY 2025
Codman Specialty Surgical
73.4%$1.2B
Tissue Technologies
26.6%$435M
NVCRNovoCure Limited

Segment breakdown not available.

ATRCAtriCure, Inc.
FY 2025
Shipping and Handling
100.0%$2M
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

AMS vs IART vs NVCR vs ATRC vs HOLX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHOLXLAGGINGATRC

Income & Cash Flow (Last 12 Months)

Evenly matched — ATRC and HOLX each lead in 3 of 6 comparable metrics.

HOLX is the larger business by revenue, generating $4.1B annually — 140.2x AMS's $29M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to IART's -30.1%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$29M$1.6B$674M$552M$4.1B
EBITDAEarnings before interest/tax$2M$209M-$165M$13M$974M
Net IncomeAfter-tax profit-$2M-$496M-$173M-$5M$544M
Free Cash FlowCash after capex-$10M-$10M-$48M$54M$1000M
Gross MarginGross profit ÷ Revenue+25.0%+39.6%+75.2%+75.5%+52.8%
Operating MarginEBIT ÷ Revenue-12.3%+5.8%-27.2%-0.4%+17.5%
Net MarginNet income ÷ Revenue-7.6%-30.1%-25.7%-0.8%+13.2%
FCF MarginFCF ÷ Revenue-34.7%-0.6%-7.1%+9.7%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+2.5%+2.4%+12.3%+14.3%+2.5%
EPS Growth (YoY)Latest quarter vs prior year-56.7%+81.8%-100.0%+101.6%-9.2%
Evenly matched — ATRC and HOLX each lead in 3 of 6 comparable metrics.

Valuation Metrics

AMS leads this category, winning 3 of 6 comparable metrics.

At 6.2x trailing earnings, AMS trades at a 80% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than ATRC's 73.2x.

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
Market CapShares × price$13M$1.1B$2.0B$1.3B$17.0B
Enterprise ValueMkt cap + debt − cash$25M$2.9B$2.2B$1.3B$17.6B
Trailing P/EPrice ÷ TTM EPS6.15x-2.07x-14.66x-109.50x30.53x
Forward P/EPrice ÷ next-FY EPS est.5.71x428.71x17.21x
PEG RatioP/E ÷ EPS growth rate0.94x
EV / EBITDAEnterprise value multiple7.54x13.14x73.24x17.39x
Price / SalesMarket cap ÷ Revenue0.47x0.66x3.11x2.49x4.14x
Price / BookPrice ÷ Book value/share0.45x1.02x5.86x2.55x3.43x
Price / FCFMarket cap ÷ FCF27.56x18.44x
AMS leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

HOLX leads this category, winning 6 of 9 comparable metrics.

HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-51 for NVCR. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IART's 1.95x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs ATRC's 5/9, reflecting strong financial health.

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity-7.9%-47.6%-50.8%-1.0%+11.0%
ROA (TTM)Return on assets-3.8%-13.7%-16.5%-0.7%+6.1%
ROICReturn on invested capital-5.8%+1.7%-16.4%-0.6%+9.4%
ROCEReturn on capital employed-6.4%+2.2%-28.9%-0.6%+8.8%
Piotroski ScoreFundamental quality 0–955557
Debt / EquityFinancial leverage0.77x1.95x0.85x0.18x0.52x
Net DebtTotal debt minus cash$12M$1.8B$187M-$79M$667M
Cash & Equiv.Liquid assets$11M$235M$103M$167M$2.0B
Total DebtShort + long-term debt$23M$2.0B$290M$88M$2.6B
Interest CoverageEBIT ÷ Interest expense-1.35x-10.36x-96.80x0.47x8.00x
HOLX leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HOLX leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in HOLX five years ago would be worth $11,678 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, HOLX leads with a +35.3% total return vs AMS's -28.5%. The 3-year compound annual growth rate (CAGR) favors HOLX at -2.9% vs NVCR's -36.4% — a key indicator of consistent wealth creation.

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-3.3%+15.9%+36.4%-33.1%+1.9%
1-Year ReturnPast 12 months-28.5%+8.0%+2.6%-15.7%+35.3%
3-Year ReturnCumulative with dividends-27.2%-72.4%-74.2%-45.0%-8.5%
5-Year ReturnCumulative with dividends-27.5%-81.1%-90.2%-64.2%+16.8%
10-Year ReturnCumulative with dividends-3.8%-62.0%+38.5%+84.4%+124.3%
CAGR (3Y)Annualised 3-year return-10.1%-34.9%-36.4%-18.1%-2.9%
HOLX leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AMS and HOLX each lead in 1 of 2 comparable metrics.

AMS is the less volatile stock with a -0.07 beta — it tends to amplify market swings less than IART's 2.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ATRC's 60.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 500-0.07x2.39x2.15x0.95x0.45x
52-Week HighHighest price in past year$3.11$16.49$20.06$43.18$76.04
52-Week LowLowest price in past year$1.25$8.70$9.82$26.10$53.62
% of 52W HighCurrent price vs 52-week peak+65.3%+84.4%+89.2%+60.9%+100.0%
RSI (14)Momentum oscillator 0–10070.570.870.944.069.1
Avg Volume (50D)Average daily shares traded144K858K1.4M678K10.3M
Evenly matched — AMS and HOLX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: IART as "Buy", NVCR as "Buy", ATRC as "Buy", HOLX as "Hold". Consensus price targets imply 95.3% upside for ATRC (target: $51) vs -13.8% for IART (target: $12).

MetricAMS logoAMSAmerican Shared H…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.HOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$12.00$33.50$51.33$79.00
# AnalystsCovering analysts26151942
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.0%0.0%+0.8%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

HOLX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). AMS leads in 1 (Valuation Metrics). 2 tied.

Best OverallHologic, Inc. (HOLX)Leads 2 of 6 categories
Loading custom metrics...

AMS vs IART vs NVCR vs ATRC vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AMS or IART or NVCR or ATRC or HOLX a better buy right now?

For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.

9% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). American Shared Hospital Services (AMS) offers the better valuation at 6. 2x trailing P/E, making it the more compelling value choice. Analysts rate Integra LifeSciences Holdings Corporation (IART) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AMS or IART or NVCR or ATRC or HOLX?

On trailing P/E, American Shared Hospital Services (AMS) is the cheapest at 6.

2x versus Hologic, Inc. at 30. 5x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — AMS or IART or NVCR or ATRC or HOLX?

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus IART's -62. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AMS or IART or NVCR or ATRC or HOLX?

By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.

07β versus Integra LifeSciences Holdings Corporation's 2. 39β — meaning IART is approximately -3640% more volatile than AMS relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — AMS or IART or NVCR or ATRC or HOLX?

By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.

9% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AMS or IART or NVCR or ATRC or HOLX?

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AMS or IART or NVCR or ATRC or HOLX more undervalued right now?

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

7x forward P/E versus 428. 7x for AtriCure, Inc. — 423. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

08

Which pays a better dividend — AMS or IART or NVCR or ATRC or HOLX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is AMS or IART or NVCR or ATRC or HOLX better for a retirement portfolio?

For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

07)). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 39 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -3. 8%, IART: -62. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AMS and IART and NVCR and ATRC and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMS is a small-cap high-growth stock; IART is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AMS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

IART

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

ATRC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 45%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AMS and IART and NVCR and ATRC and HOLX on the metrics below

Revenue Growth>
%
(AMS: 2.5% · IART: 2.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.